Clinical Trials Logo

Left Atrial Appendage Thrombosis clinical trials

View clinical trials related to Left Atrial Appendage Thrombosis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06007872 Recruiting - Atrial Fibrillation Clinical Trials

Intracardiac Echocardiography Guided Watchman Device Implant

Start date: December 2, 2022
Phase: N/A
Study type: Interventional

This study is to look at the success of Intracardiac Echocardiography (ICE) in the Watchman procedure. Currently the process is to use a Transesophageal Echocardiography (TEE) to place the Watchman in patients. This study is aiming to show how the ICE is just as effective in placing the device correctly and effectively.

NCT ID: NCT04135677 Recruiting - Stroke Clinical Trials

Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO

Start date: November 11, 2022
Phase: Phase 4
Study type: Interventional

The objective of this study is to assess the efficacy and safety different dosage of rivaroxaban application versus dual antiplatelet therapy after successful closure of left atrial appendage using the LAMBRE device.

NCT ID: NCT03840291 Recruiting - Atrial Fibrillation Clinical Trials

Resolution of Thrombi in Left Atrial Appendage With Edoxaban

REFLEX
Start date: May 19, 2019
Phase: Phase 4
Study type: Interventional

Non-valvular (NV) atrial fibrillation (AF) increases the risk of stroke by approximately fivefold. The atrial thrombi associated with AF are seen within the left atrial appendage (LAA) in most cases (> 90%). Anticoagulation with a vitamin-K antagonist (VKA) is recommended to prevent thromboembolic complications and to resolve thrombi. Non-VKA oral anticoagulants (NOACs) have replaced the VKA for the thromboprophylaxis in patients with NVAF since 2010. Therefore, NOAC can be the excellent alternative to VKA concerning resolving preexisting LAA thrombi because of its rapid onset of action and no need of bridging with heparin. However, there is still lack of data regarding the optimal treatment for patients with AF and thrombi in LAA with NOAC. There are only several case reports of the efficacy of NOACs in resolving LAA thrombi available. Edoxaban, which has data showing efficacy and safety in thromboprophylaxis, can be the new option for treatment of patients with AF and LAA thrombi. The purpose of this study is to evaluate the efficacy of Edoxaban in resolving the LAA thrombi, which is related with nonvalvular AF.